Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
Rachel G. Liao(Broad Institute), Peter S. Hammerman(Broad Institute), Kwok‐Kin Wong(NYU Langone Health), Nathanael S. Gray(Stanford University), Andrey Sivachenko(Broad Institute), Matthew D. Wilkerson(Uniformed Services University of the Health Sciences), Matthew Meyerson(Broad Institute), D. Neil Hayes(University of North Carolina at Chapel Hill), Trevor J. Pugh(Boston Children's Hospital), Jeremy H. Tchaicha(Broad Institute), Robert I. Haddad(Georgetown University), Chandra Sekhar Pedamallu(Broad Institute), Joonil Jung(Broad Institute), Ellen M. Beauchamp(Broad Institute), Qingsong Liu(Medical College of Wisconsin), Gad Getz(Broad Institute)
Cited by 168
Related Papers
Integrative genomics viewer
|Nature Biotechnology|2011|16.5k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k